Building a Succinate Accumulation Model
Three Ways to Raise Succinate
| Approach | Mechanism | Speed | Caveat |
|---|---|---|---|
| SDH inhibition (malonate, TTFA, 3-NPA) | Competitive or irreversible inhibition of complex II | Minutes to hours | Off-target effects; competitive with succinate |
| SDH subunit knockout (SDHA–D) | Loss of complex II | Weeks | Lethality in some lines; adaptation |
| FH loss | Fumarate accumulates and back-fluxes to succinate | Weeks | Both metabolites rise; effects overlap |
| Ischaemia or reoxygenation models | Reverse SDH flux during ischaemia | Minutes | Transient; difficult to control |
Important distinction. SDH inhibition raises succinate by blocking its oxidation; FH loss raises succinate indirectly by mass action through reversible fumarase. The two produce different accompanying metabolite changes — fumarate is high in both, but the ratio differs — and the downstream effects are not identical.
Part 1 — The Compartment Problem
| Compartment | What accumulates | How to measure |
|---|---|---|
| Mitochondrial matrix | Millimolar succinate in SDH-deficient models | Mitochondrial isolation; or inferred from downstream effects |
| Cytosol | Lower and less certain | Fractionation; metabolite biosensors |
| Extracellular | Exported; measurable in medium | Medium LC-MS |
Caveat on whole-cell values. A whole-cell succinate measurement is dominated by the mitochondrial pool, which is thousands of times larger in volume-normalised terms than the cytosolic pool in some cells. A rise in the whole-cell value can occur with little change in the cytosolic concentration that would reach a nuclear dioxygenase.
Readout note. The practical consequence is that a succinate claim should be paired with a downstream readout that reports the effect rather than the concentration — PHD activity via HIF, or a demethylase effect via a methylation mark — because those integrate concentration and compartment into a functional endpoint.
Part 2 — Inhibitor Choices
| Agent | Target | Reversibility | Note |
|---|---|---|---|
| Malonate | Complex II, competitive with succinate | Reversible | Requires high concentrations; competes with the substrate |
| TTFA | Complex II, Q-site | Reversible | Weak; high concentrations needed |
| 3-Nitropropionate | Complex II, irreversible | Irreversible | Recovery requires new enzyme |
| Dimethyl malonate | Cell-permeable prodrug | Reversible | Used in vivo; esterase-dependent |
Caveat on malonate. Because malonate competes with succinate at the same site, raising succinate concentration partially overcomes the inhibition. In a model where succinate accumulates, the inhibitor's effective potency falls — which can produce a plateau that looks like a saturable biological effect.
Part 3 — Building the Genetic Model
| Step | Requirement | Note |
|---|---|---|
| Target | SDHB (soluble, stable) is often chosen for complete loss | SDHA loss can be tolerated in some lines |
| Editing | Two independent guides; or inducible | Lethality requires inducibility |
| Selection | Growth in uridine-free or specific conditions if needed | Complex II loss does not require uridine |
| Verification | Subunit immunoblot; complex II activity; succinate measurement | Three levels |
| Phenotype | HIF or methylation readout | Concentration alone is insufficient |
| Comparator | Isogenic wild-type at matched passage | Adaptation confound |
Readout note. Complex II is entirely nuclear-encoded, so SDH knockouts are straightforward genetically; but the metabolic consequences include accumulation of both succinate and, in some settings, ROS from the altered Q pool. A phenotype in an SDH knockout is therefore not exclusively a succinate phenotype.
Part 4 — What the Model Supports
| Claim | Requires | Not sufficient |
|---|---|---|
| "Succinate accumulated" | Quantified succinate, with compartment inference | A fold-change in whole cells |
| "PHD was inhibited" | HIF stabilisation with a PHD-dependent readout, or PHD activity | HIF protein alone |
| "DNA methylation changed" | 5mC/5hmC measurement with a demethylase-dependent design | A single locus |
| "Succinate mediates the phenotype" | Succinate-lowering rescue, or comparison with an SDH-independent succinate source | Correlation |
| "The model recapitulates SDH-deficient tumours" | Genotype plus metabolite plus phenotype concordance | Any one of the three |
Part 5 — Common Failures
- • Whole-cell succinate used to infer nuclear enzyme inhibition.
- • Malonate described as a specific SDH inhibitor without noting substrate competition.
- • FH loss used as a "succinate model", when fumarate is the distinguishing metabolite.
- • HIF stabilisation attributed to succinate without excluding other PHD inhibitors in the model.
- • Knockout verified by genotype only.
- • No isogenic comparator, so adaptation is confounded with genotype.
- • Succinate measured at a single timepoint, before the pool has equilibrated.
- • Inhibitor concentrations taken from the literature without a dose–response.
Part 6 — Where This Article Connects
This is the model-building article of the mitochondrial cluster, paired with the oncometabolite article that covers the dioxygenase logic. It connects to the 2-HG detection article, where the enantiomer problem is analogous, and to the respiratory chain article, where complex II's nuclear encoding is discussed.
If you need succinate models with compartment inference and downstream functional readouts, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Succinate accumulation, compartment distribution and downstream effects vary with the lesion, cell type and time after perturbation. The models here are described at the level of principle.
An increased succinate concentration does not establish inhibition of a specific dioxygenase, and a phenotype in an SDH-deficient model is not exclusively a succinate phenotype.
Scientific interpretation and experimental design
- • Compartment is the issue. Whole-cell values are dominated by mitochondria.
- • Add a functional readout. HIF or methylation.
- • Malonate competes with succinate. Potency falls as succinate rises.
- • FH loss is not an SDH model.
- • Verify at three levels.
- • Isogenic comparator, matched passage.
Selected references for further reading
- • Selak MA, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005;7:77–85.
- • Xiao M, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate. Genes & Development. 2012;26:1326–1338.
- • Chouchani ET, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–435.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »